Holen Sie sich die Stockscreener-App
4.82
0.85%
0.09
Schlusskurs vom Vortag:
$4.73
Offen:
$4.9
24-Stunden-Volumen:
23,299
Relative Volume:
0.08
Marktkapitalisierung:
$298.64M
Einnahmen:
$45.15M
Nettoeinkommen (Verlust:
$-39.23M
KGV:
-2.6353
EPS:
-1.829
Netto-Cashflow:
$-18.93M
1W Leistung:
-7.20%
1M Leistung:
-14.97%
6M Leistung:
+3.36%
1J Leistung:
-2.65%
1-Tages-Spanne:
$4.68
$4.90
1-Wochen-Bereich:
$4.48
$5.37
52-Wochen-Spanne:
$2.20
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Firmenname
Trisalus Life Sciences Inc
Sektor
Branche
Telefon
415 336 8917
Adresse
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
4.85 | 291.25M | 45.15M | -39.23M | -18.93M | -1.829 |
ABT
Abbott Laboratories
|
106.02 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.81 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
273.46 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.59 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.44 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Eingeleitet | Lake Street | Buy |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-11-11 | Eingeleitet | ROTH MKM | Buy |
| 2024-10-25 | Eingeleitet | Northland Capital | Outperform |
| 2024-09-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-30 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Trisalus Life Sciences Inc Aktie (TLSI) Neueste Nachrichten
This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TriSalus Life Sciences (TLSI) Climbs 1.55% as Support Holds Above $4.99Wyckoff Distribution - vinanet.vn
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference - Business Wire
TriSalus Life Sciences (TLSI) Slips 2% as Shares Test Key $4.59 Support LevelKey Reversal Day - dars.gov.et
TriSalus (TLSI) Results Review: The Bottom-Line Figure Trails Its Comparison in the Available Record; Share Response: Shares Move 3.04% Lower in the Latest SessionWeak Earnings Momentum - vinanet.vn
TriSalus (TLSI) Market: Falls 2.18% to $5.16 on the Day; Technical Setup: the Near-Term Reference Band Stretches From $4.90 to $5.42 on the DayETF NAV Deviation - vinanet.vn
TriSalus Life Sciences, Inc. (TLSI) Reports Q1 Loss, Lags Revenue Estimates - Eastern Progress
TriSalus (TLSI) Latest Quarter: The Bottom-Line Figure Trails Its Comparison for This Review; Price Move: Shares Finish 2.47% Up in the Current UpdateSegment Revenue Breakdown - vinanet.vn
TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Cut to "Sell" at Wall Street Zen - MarketBeat
TriSalus Life Sciences Warrant (TLSIW) Plunges 55%: Critical Support Test at $0.53AAII Bullish - vinanet.vn
CCORF Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
TriSalus Life Sciences Inc (TLSI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Trisalus Life Sciences at Canaccord Genuity: growth bets build By Investing.com - Investing.com Nigeria
Trisalus Life Sciences at Canaccord Genuity: growth bets build - Investing.com
TriSalus Life Sciences (TLSI) Advances 2.87% as Shares Hold Above $5.45 SupportETH Profile - dars.gov.et
Maxim Group Maintains TriSalus Life Sciences(TLSI.US) With Buy Rating, Raises Target Price to $14 - Moomoo
TLSI Q2 2026 Earnings: EPS Misses Slightly as Liver-Tumor Focus ContinuesRetail Earnings Report - vinanet.vn
TriSalus Life Sciences (TLSI) Dips 4.3% to $5.37 as Shares Approach Key Support ZoneWedge Breakout - dars.gov.et
TriSalus Life Sciences earnings missed by $0.01, revenue topped estimates - Investing.com Canada
TriSalus Life Sciences (TLSI) Stock Surges As Losses Deepen Behind Strong Margins - Sahm
Securities Fraud Investigation Into TriSalus Life Sciences Inc - The National Law Review
TriSalus Life Sciences, Inc. (TLSI) stock price, news, quote and history - Yahoo Finance UK
TriSalus Life Sciences (NASDAQ:TLSI) Posts Quarterly Earnings Results, Meets Expectations - MarketBeat
TriSalus Life Sciences, Inc. Revenue Breakdown – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Q2 Earnings Call Highlights - marketbeat.com
Price to earnings forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc (TLSI) (Q2 2026) Earnings Call Highlights: New CMS G-code Expands ... - Yahoo Finance
Earnings call transcript: TriSalus tops Q2 revenue forecast, stock slips after hours - Investing.com
Price to sales forward of TriSalus Life Sciences, Inc. – NASDAQ:TLSIW - TradingView
TriSalus Life Sciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
TLSI: Q2 revenue rose to $11.4M, with expanded OBL reimbursement and strong growth outlook - TradingView
TriSalus Q2 2026 Earnings: Gross Margin Rises as Operating Loss Widens - TradingKey
TriSalus Life Sciences, Inc. 2026: Revenue $11.41M, EPS ($0.16) — 10-Q Summary - TradingView
TriSalus Life Sciences Reports Second Quarter 2026 Results - marketscreener.com
Inside TriSalus Life Sciences (NASDAQ: TLSI) Q2 2026 performance - Stock Titan
TriSalus Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TLSI: Q2 revenue up 1.7% to $11.4M, gross margin 88%, and 2026 guidance reaffirmed at $54–$57M - TradingView
TriSalus Life Sciences (TLSI) Gains 1.3% as Stock Holds Above Key SupportSell Signal Alerts - vinanet.vn
Earnings To Watch: TriSalus Life Sciences Inc (TLSI) Q2 2026 -- GF Value Sees 20% Upside - Yahoo Finance
TriSalus Life Sciences Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
TLSI Q1 2026 Earnings: Unexpected Profit of $0.03 Overwhelmingly Beats Loss EstimateOne-Time Gain Impact - vinanet.vn
TLSI Q1 2026 Earnings: EPS of $0.03 Beats Estimates with a 118.86% Positive SurpriseBalance Sheet Strength - vinanet.vn
TriSalus Life Sciences (TLSI) Stock Forum and Discussion - Moomoo
TriSalus Life Sciences Q1 2026 Earnings: EPS Surprise of 118.86% Beats Estimates Despite No Reported RevenueROA Comparison - dars.gov.et
TriSalus CEO and CFO to Join Canaccord Fireside Chat Aug. 12 - Stock Titan
TriSalus Life Sciences Inc (TLSI) Cash Flow - TradingKey
TriSalus Life Sciences Inc (TLSI) Valuation: PE, PB & Fair Value Analysis - TradingKey
TriSalus Life Sciences Inc (TLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TriSalus Life Sciences Inc (TLSI) Balance Sheet - TradingKey
First Light Asset Management LLC Invests $20.27 Million in TriSalus Life Sciences, Inc. $TLSI - MarketBeat
Finanzdaten der Trisalus Life Sciences Inc-Aktie (TLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trisalus Life Sciences Inc-Aktie (TLSI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Wahlstrom Mats | Director |
May 15 '26 |
Buy |
2.53 |
60,000 |
151,800 |
147,555 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
410,000 |
1,025,000 |
1,240,722 |
| Stansky Michael P | Director |
May 15 '26 |
Buy |
2.50 |
200,000 |
500,000 |
399,698 |
| Szela Mary T | CEO and President |
May 15 '26 |
Buy |
2.59 |
39,682 |
102,776 |
1,065,215 |
| Patience David | Chief Financial Officer |
May 15 '26 |
Buy |
2.43 |
7,100 |
17,253 |
275,757 |
| Gordon Gary B. | Director |
May 15 '26 |
Buy |
2.46 |
10,000 |
24,600 |
72,510 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 12 '26 |
Sale |
4.09 |
1,772 |
7,247 |
97,637 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 11 '26 |
Sale |
4.13 |
1,162 |
4,799 |
99,409 |
| Devlin Jodi | Chief of Clinical Operations |
Mar 16 '26 |
Sale |
4.12 |
273 |
1,125 |
97,364 |
| Cox Bryan F. | Chief of Research |
Mar 12 '26 |
Sale |
4.09 |
1,467 |
6,000 |
163,994 |
0.72%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):